NECLIFEPharmaceuticals
Nectar Lifesciences Ltd — Cash Flow Statement
₹9.30
-7.74%
Nectar Lifesciences Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 125.64 Cr | 195.27 Cr | 103.59 Cr | 70.03 Cr | — |
| Capital Expenditure | -43.79 Cr | -29.42 Cr | -30.06 Cr | -24.97 Cr | — |
| End Cash Position | 19.22 Cr | 19.81 Cr | 17.58 Cr | 17.81 Cr | — |
| Beginning Cash Position | 19.81 Cr | 17.58 Cr | 17.81 Cr | 25.54 Cr | — |
| Changes In Cash | -0.58 Cr | 2.23 Cr | -0.23 Cr | -7.73 Cr | — |
| Financing Cash Flow | -128.09 Cr | -205.43 Cr | -185.58 Cr | -119.38 Cr | — |
| Interest Paid Cff | -74.58 Cr | -87.14 Cr | -79.49 Cr | -78.81 Cr | — |
| Net Issuance Payments Of Debt | -53.51 Cr | -118.29 Cr | -109.10 Cr | -50.57 Cr | — |
| Net Short Term Debt Issuance | 28.00 Cr | -46.69 Cr | -43.86 Cr | -206.32 Cr | — |
| Net Long Term Debt Issuance | -81.51 Cr | -71.60 Cr | -65.24 Cr | 155.75 Cr | — |
| Investing Cash Flow | -41.93 Cr | -17.03 Cr | 51.70 Cr | 16.64 Cr | — |
| Net Other Investing Changes | 0.37 Cr | — | — | -10000.00 | — |
| Interest Received Cfi | 1.49 Cr | 12.39 Cr | 1.73 Cr | 1.88 Cr | — |
| Dividends Received Cfi | 0.00 | 0.00 | 0.00 | 10000.00 | — |
| Net Investment Purchase And Sale | 0.00 | 0.00 | 0.25 Cr | 0.00 | — |
| Net PPE Purchase And Sale | -43.79 Cr | -29.42 Cr | 49.73 Cr | 14.76 Cr | — |
| Sale Of PPE | 83000.00 | 0.00 | 79.79 Cr | 39.73 Cr | — |
| Purchase Of PPE | -43.79 Cr | -29.42 Cr | -30.06 Cr | -24.97 Cr | — |
| Operating Cash Flow | 169.44 Cr | 224.69 Cr | 133.65 Cr | 95.00 Cr | — |
| Taxes Refund Paid | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Change In Working Capital | 191.95 Cr | 68.87 Cr | 77.93 Cr | -64.54 Cr | — |
| Change In Other Current Liabilities | 21.33 Cr | 113.63 Cr | -72.43 Cr | 18.67 Cr | — |
| Change In Other Current Assets | 170.62 Cr | -44.77 Cr | 150.35 Cr | -83.21 Cr | — |
| Other Non Cash Items | 73.26 Cr | 74.41 Cr | 78.63 Cr | 77.76 Cr | — |
| Provisionand Write Offof Assets | 1.61 Cr | 0.93 Cr | 0.22 Cr | 0.96 Cr | — |
| Deferred Tax | 0.29 Cr | -0.18 Cr | 0.47 Cr | 0.45 Cr | — |
| Depreciation And Amortization | 62.39 Cr | 60.72 Cr | 59.12 Cr | 56.97 Cr | — |
| Depreciation | 62.39 Cr | 60.72 Cr | 50.11 Cr | 49.07 Cr | — |
| Pension And Employee Benefit Expense | 1.49 Cr | 1.85 Cr | 0.21 Cr | -1.26 Cr | — |
| Gain Loss On Investment Securities | -0.03 Cr | -0.18 Cr | -0.10 Cr | -30000.00 | — |
| Gain Loss On Sale Of PPE | 0.01 Cr | 0.00 | -40.41 Cr | -9.41 Cr | — |
| Net Income From Continuing Operations | -161.53 Cr | 18.27 Cr | -42.42 Cr | 34.08 Cr | — |
| Amortization Cash Flow | — | 11.29 Cr | 9.01 Cr | 7.89 Cr | — |
| Net Other Financing Charges | — | — | 3.00 Cr | 10.00 Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | — | — | -1000.00 | — |
| Cash Dividends Paid | — | — | — | — | -1.12 Cr |
| Purchase Of Investment | — | — | — | — | -0.25 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Nectar Lifesciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.